Texas to have sales tax holiday on emergency supplies from April 26-28
The holiday will begin at 12:01 a.m. on April 26 and will end at midnight on April 28, according to the press release.
'While we can't know in advance when the next fire, flood, tornado or hurricane may occur, we can make sure our families, homes and businesses have the supplies they need to face these and other emergencies,' Hegar said. 'Don't wait for disaster to strike. I'm encouraging Texans to take advantage of this tax holiday to save money while stocking up for emergency situations.'
The comptroller's office said it estimates shoppers to save about $2.3 million in state and local sales taxes during the holiday. The holiday was first approved by the Texas Legislature in 2015.
Qualifying items that you can purchase include:
Household batteries, fuel containers, and flashlights priced less than $75;
Hurricane shutters and emergency ladders priced less than $300
Portable generators priced less than $3,000.
Purchases that do not qualify include:
Batteries for automobiles, boats and other motorized vehicles
Camping stoves and camping supplies
Chainsaws
Plywood
Extension ladders and stepladders
Tents
The Texas Comptroller's website has a complete list of items that qualify for the sales tax holiday.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Planview Again Named by Gartner® as a Leader in Strategic Portfolio Management
AUSTIN, Texas--(BUSINESS WIRE)-- Planview, the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), today announced that it was named a Leader in the 2025 Gartner® Magic Quadrant™ for Strategic Portfolio Management (SPM) 1. This is the fourth consecutive year that the company has been recognized, receiving the highest and furthest position in both Completeness of Vision and Ability to Execute indices. "In today's rapidly evolving technology environment, shaped increasingly by AI, organizations must evolve their portfolio management practices to better connect strategic intent to execution," said Louise K. Allen, Chief Product Officer at Planview. "By supporting the shift to a product operating model, Planview enables teams to focus less on finishing projects and more on achieving the outcomes that matter most." Planview® Portfolios' comprehensive and mature build is a key differentiator, as is the company's commitment to continuous improvement, integrating emerging technology, and strong industry partnerships. In the past year, Planview has also demonstrated its ongoing dedication to bringing advanced planning capabilities to a wide range of businesses across regions and sectors. Highest Scores in Critical Capabilities Planview was also recognized in the Gartner® companion report to the Magic Quadrant, the Critical Capabilities for Strategic Portfolio Management 2. A Critical Capabilities document is a comparative analysis that scores competing products or services against a set of critical differentiators identified by Gartner. Planview received the highest score in three of three Use Cases: Strategy Execution Management, Enterprise Program and Portfolio Management, and Integrated IT Portfolio Analysis. Download a complimentary copy of The 2025 Gartner® Magic Quadrant™ for Strategic Portfolio Management (SPM) report to read the full assessment. To learn more about Planview, visit Gartner does not endorse any vendor, product, or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose. GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, and MAGIC QUADRANT is a registered trademark of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved. About Planview Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Development (DPD), giving its customers the strategic foresight to prioritize investments and initiatives, make those plans real within constraints, and pivot with certainty when things change. Our connected platform of solutions underpins the business and digital transformations of more than 2.7 million users globally, including 45 of the Fortune 100. Headquartered in Austin, Texas, Planview has over 1,300 employees worldwide.
Business Wire
an hour ago
- Business Wire
Rosen Law Firm Urges Altimmune, Inc. (NASDAQ: ALT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025. Altimmune describes itself as a 'clinical stage biopharmaceutical company focused on developing treatments for obesity, metabolic and liver diseases.' For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653. The Allegations: Rosen Law Firm is Investigating the Allegations that Altimmune, Inc. (NASDAQ: ALT) Misled Investors Regarding its Business Operations. According to the lawsuit, defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to the results of Altimmune's IMPACT Phase 2b MASH trial. In truth, Altimmune failed to meet an important statistical significance marker relating to the fibrosis reduction primary endpoint. Altimmune had consistently touted its inflated expectations for positive topline results from the IMPACT Phase 2b MASH trial, while concealing higher responses in the placebo group, which they knew or should have known would negatively impact the topline results. Altimmune's IMPACT Phase 2b MASH trial results fell short of reality, as shown by Altimmune's topline data, which show that the statistical significance was not achieved for the fibrosis reduction primary endpoint. When the true details entered the market, the lawsuit claims that investors suffered damages. What Now: You may be eligible to participate in the class action against Altimmune, Inc. Shareholders who want to serve as lead plaintiff for the class must file their motions with the court by October 6, 2025. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here. All representation is on a contingency fee basis. Shareholders pay no fees or expenses. About Rosen Law Firm: Some law firms issuing releases about this matter do not actually litigate securities class actions. Rosen Law Firm does. Rosen Law Firm is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses, improving corporate governance structures, and holding company executives accountable for their wrongdoing. Since its inception, Rosen Law Firm has obtained over $1 billion for shareholders. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome.
Yahoo
an hour ago
- Yahoo
Corpay Earnings Meet Estimates in Q2, Revenues Increase 13% Y/Y
Corpay, Inc.'s CPAY second-quarter 2025 earnings per share met the consensus mark, while revenues beat the same. CPAY's earnings per share of $5.13 met the consensus estimate by a slight margin and increased 12.8% year over year. The total revenues of $1.1 billion beat the consensus estimate by a slight margin and gained 13% from the year-ago quarter. The stock has declined 6.9% over the year-to-date period against its industry's marginal rise and 6.9% growth of the Zacks S&P 500 composite. Corpay, Inc. Price, Consensus and EPS Surprise Corpay, Inc. price-consensus-eps-surprise-chart | Corpay, Inc. Quote Corpay's Segmental Results Vehicle payments' revenues of $525.5 million increased 3% from the year-ago quarter. This figure beat our estimate of $523.3 million. Revenues from corporate payments amounted to $391.9 million, up 36% year over year, missing our projection of $392.1 million. Lodging payments posted revenues of $119.8 million, declining 2% from the year-ago quarter. The reported figure missed our estimate of $123.8 million. CPAY's Margins EBITDA increased 10.2% from the year-ago quarter to $570.7 million, surpassing our estimation of $568.4 million. The EBITDA margin was 56.3%, down 50 basis points from the year-ago quarter. Balance Sheet & Cash Flow of CPAY Corpay exited the second quarter of 2025 with cash and cash equivalents of $2.2 billion compared with $1.6 billion in the first quarter of 2025. The long-term debt was $5.9 billion, flat with the preceding quarter. CPAY utilized $1.1 billion million in cash from operating activities in the quarter. Capital expenditure amounted to $52.6 million. Corpay's 2025 Outlook For 2025, CPAY raised the revenue guidance to $4.41-$4.49 billion from $4.38-$4.46 billion provided in the preceding quarter. The mid-point ($4.45 billion) of the guided range is higher than the Zacks Consensus Estimate of $4.44 billion. The guidance for adjusted net income per diluted share was hiked to $20.86-$21.26 from the preceding quarter's view of $20.80-$21.20. The mid-point ($21.06) of the guided range is slightly lower than the Zacks Consensus Estimate of $21.10. Currently, CPAY carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Earnings Snapshot Gartner, Inc. IT reported second-quarter 2025 results, wherein earnings and revenues surpassed the Zacks Consensus Estimate. IT's adjusted earnings per share of $3.53 beat the Zacks Consensus Estimate by 4.4% and increased 9.6% from the year-ago quarter. Revenues of $1.7 billion beat the consensus estimate by a slight margin and improved 5.7% year over year. Verisk VRSK reported impressive second-quarter fiscal 2025 results. VRSK's adjusted earnings were $1.88 per share, surpassing the Zacks Consensus Estimate by 6.2% and increasing 8.1% from the year-ago quarter. Total revenues of $772.6 million beat the consensus estimate marginally and increased 7.8% on a year-over-year basis. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gartner, Inc. (IT) : Free Stock Analysis Report Verisk Analytics, Inc. (VRSK) : Free Stock Analysis Report Corpay, Inc. (CPAY) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
